{"url_path":"/sec/axsm/8-k/2026-07-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1579428/0001193125-26-304039-index.html","accession_number":"0001193125-26-304039","cik":"0001579428","ticker":"AXSM","issuer_name":"Axsome Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1579428/0001193125-26-304039-index.html","primary_entity_key":"0001579428","primary_entity_name":"Axsome Therapeutics, Inc."},"word_count":63,"has_tables":true,"body_markdown":"## Item 8.01 Other Events.\n\nOn July 15, 2026, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy.\n\nThe full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference."}